AstraZeneca is giving Pascal Soriot a pay raise as the longtime CEO weathered a year of “significant geopolitical uncertainty ...

The agreement ends litigation between the Swiss company and the estate of Henrietta Lacks, which filed a lawsuit in federal court in Baltimore against Novartis and Viatris in August 2024. The family ...

Still, broad uptake has long been an uphill battle for the gene therapy as it competes with a variety of treatments including, Roche’s blockbuster Hemlibra, Sanofi’s newer sales driver Altuviiio and ...

Four years after the FDA issued its most heavy-handed form of a rejection to the prior company behind pegzilarginase, the U.S. regulator has now given the treatment a thumbs-up. | Four years after the ...

More recently, Pfizer splashed out $150 million upfront—and put up hundreds of millions more in potential milestones—to acquire worldwide rights to a GLP-1 agonist dubbed YP05002 from Yao Pharma, a ...

Amid efforts on several fronts to improve the affordability of its GLP-1 medications for diabetes and obesity, Novo Nordisk is taking a new approach by aiming straight for semaglutide’s list price. | ...

With a new corporate sponsorship in hand, Ardelyx is aiming for a hole-in-one in the awareness-raising game. | With a new corporate sponsorship in hand, Ardelyx is aiming for a hole-in-one in the ...

Indivior has picked Havas as its primary partner for engaging healthcare professionals and patients in the U.S.  | Havas will lead Indivior’s integrated strategy, creative, media and digital efforts ...

Roche’s autoimmune drug Enspryng is making solid progress as a treatment for neuromyelitis optica spectrum disorder (NMOSD).

At least one major partner has pumped the brakes on a deal that the president’s import taxes helped facilitate last summer.

AbbVie’s $100 billion splurge on domestic manufacturing and R&D is continuing to come into focus, this time with a $380 million investment in two new active pharmaceutical ingredient manufactur | The ...

Bayer has filed a false advertising lawsuit taking issue with claims made by Johnson & Johnson to pit their prostate cancer drugs against one another. | Bayer has filed a false advertising lawsuit ...